SCHEMBL6725920

SCHEMBL6725920

O=C(c1ccc(-c2ccncc2)cc1)N1C2CC(N3CCOCC3)CC1CN(S(=O)(=O)c1ccc3cc(Cl)ccc3c1)C2

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
F10 P00742 8/20 0.46
ATM Q13315 2/20 0.42
KDM4E B2RXH2 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
ALDH1A1 P00352 2/20 0.42
MKNK1 Q9BUB5 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
CHRM1 P11229 1/20 0.40
LMNA P02545 3/20 0.39
GAA P10253 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
F2 P00734 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
HSD17B10 Q99714 1/20 0.39
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6731011 0.92 F10 (0.45) F10ATMKDM4ESMN1; SMN2ALDH1A1
SCHEMBL6729129 0.91 F10 (0.46) F10ATMCHRM1L3MBTL1F2
SCHEMBL6738164 0.89 ALDH1A1 (0.42) F10KDM4ESMN1; SMN2ALDH1A1LMNA
SCHEMBL6737137 0.87 F10 (0.46) F10ATMKDM4ESMN1; SMN2CHRM1
SCHEMBL6730749 0.84 F10 (0.43) F10ATMKDM4ESMN1; SMN2CHRM1
SCHEMBL6736744 0.84 F10 (0.43) F10ATMKDM4ESMN1; SMN2CHRM1
SCHEMBL6733779 0.83 F10 (0.43) F10ATMKDM4ESMN1; SMN2CHRM1
SCHEMBL6734456 0.81 F10 (0.42) F10ALDH1A1LMNAL3MBTL1F2
SCHEMBL6729352 0.81 F10 (0.46) F10KDM4EALDH1A1L3MBTL1F2
SCHEMBL6734441 0.80 F10 (0.47) F10ATMKDM4ESMN1; SMN2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6747023-B1 INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-08 US disclosed
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-29 US disclosed
EP-1104754-A1 NOVEL SULFONYL DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-06-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction F2, CYC1, SULT2A1 F10 19/4885ATM 2080/4885KDM4E 3346/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.